PT  - JOURNAL ARTICLE
AU  - Raghav, Sunil K.
AU  - Sen, Kaushik
AU  - Ghosh, Arup
AU  - Datta, Sudeshna
AU  - Ahad, Abdul
AU  - Jha, Atimukta
AU  - Chatterjee, Sanchari
AU  - Suranjika, Sandhya
AU  - Sengupta, Soumya
AU  - Bhattacharya, Gargee
AU  - Shriwas, Omprakash
AU  - Avula, Kiran
AU  - Kshatri, Jayasingh
AU  - Prasad, Punit
AU  - Parida, Ajay K.
TI  - SARS-CoV-2 specific immune-signature in direct contacts of COVID-19 cases protect them from contracting disease: A Retrospective Study
AID  - 10.1101/2021.03.11.21253367
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.11.21253367
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253367.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253367.full
AB  - The response to SARS-CoV-2 is largely impacted by the level of exposure and the status of immunity. The nature of protection shown by direct contacts of COVID-19 positive patients is quite intriguing to note. We aimed to study the immune differences reinforcing contact individuals in circumventing the disease. Our observation showed direct contacts of PCR positive patients developed elevated neutralizing antibody titres and cytokine levels. On the other hand, single cell data revealed differential usage of V(D)J genes and unique BCR clonotypes imparting protective immune signatures.Topics serologic tests, immunoglobulin a, immunoglobulin g, immunoglobulin m, antibody titre; cytokine levels; virus neutralization; V(D)J sequencing; BCR clonotypesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the Department of Biotechnology, Government of India and the Odisha state government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The blood samples for this study were obtained from TATA COVID hospital, Ganjam District, Odisha after due approval of the Institutional Biosafety and human ethics committee (Ref: 101/HEC/2020). For collecting the blood samples for the study due consent was taken from the subjects involved in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available with the corresponding author and will be shared on request.